| |
|
HCC | Abstract Library |
 |
| |
| The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
| |
|
|
| |
|
|
| |
| 4. | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study |
| |
Lancet. 2023 Sep 30;402(10408):1133-1146.doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.
Shukui Qin 1, Stephen L Chan 2, Shanzhi Gu 3, Yuxian Bai 4, Zhenggang Ren 5, Xiaoyan Lin 6, Zhendong Chen 7, Weidong Jia 8, Yongdong Jin 9, Yabing Guo 10, Xiaohua Hu 11, Zhiqiang Meng 12, Jun Liang 13, Ying Cheng 14, Jianping Xiong 15, Hong Ren 16, Fang Yang 17, Wei Li 18, Yajin Chen 19, Yong Zeng 20, Alexander Sultanbaev 21, Monika Pazgan-Simon 22, Margaryta Pisetska 23, Davide Melisi 24, Dmitriy Ponomarenko 25, Yurii Osypchuk 26, Ivan Sinielnikov 27, Tsai-Sheng Yang 28, Xiao Liang 29, Chunxia Chen 29, Linna Wang 29, Ann-Lii Cheng 30, Ahmed Kaseb 31, Arndt Vogel 32; CARES-310 Study Group
Collaborators
Shukui Qin, Stephen L Chan, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Yurii Osypchuk, Ivan Sinielnikov, Tsai-Sheng Yang, Xiao Liang, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Ping Hao, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bozena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, Marina Nechaeva, Chia-Jui Yen, Wei-Wen Su, Yen-Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gomez-Martin, Min-Hee Ryu, Han-Sang Kim, Jee-Hyun Kim, Oleg Zarubenkov, Rashida Orlova, Elena Poddubskaya, Natalia Fadeeva, Yulia Makarova, Yee Chao, Chao-Hung Hung, Maryna Neffa, Oleksandr Vynnychenko, Adam Burgoyne, Chunyi Hao, Raphael U Mohr, Roberto Diaz-Beveridge, Jaime Feliu-Batlle, Antonio Cubillo-Gracian, Ann-Shing Lee, Bruno Daniele, Lorenzo Antonuzzo, Angelo Sangiovanni, Antonio Gasbarrini, Mario Scartozzi, Mi Sun Ahn, Sung-Yong Oh, Sergey Orlov, Hakan Harputluoglu, Berna Oksuzoglu, Chiun Hsu, Kun-Ming Rau, Oleksandr Krechkovskyi, Vladimir Yareshko, Henry Xiong, Fa-Chyi Lee, Yixing Jiang, Afshin Gabayan, Mary Crow, Christophe Van Steenkiste, Gontran Verset
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 9. | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study |
| |
Lancet. 2023 Sep 30;402(10408):1133-1146.doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.
Shukui Qin 1, Stephen L Chan 2, Shanzhi Gu 3, Yuxian Bai 4, Zhenggang Ren 5, Xiaoyan Lin 6, Zhendong Chen 7, Weidong Jia 8, Yongdong Jin 9, Yabing Guo 10, Xiaohua Hu 11, Zhiqiang Meng 12, Jun Liang 13, Ying Cheng 14, Jianping Xiong 15, Hong Ren 16, Fang Yang 17, Wei Li 18, Yajin Chen 19, Yong Zeng 20, Alexander Sultanbaev 21, Monika Pazgan-Simon 22, Margaryta Pisetska 23, Davide Melisi 24, Dmitriy Ponomarenko 25, Yurii Osypchuk 26, Ivan Sinielnikov 27, Tsai-Sheng Yang 28, Xiao Liang 29, Chunxia Chen 29, Linna Wang 29, Ann-Lii Cheng 30, Ahmed Kaseb 31, Arndt Vogel 32; CARES-310 Study Group
Collaborators
Shukui Qin, Stephen L Chan, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Yurii Osypchuk, Ivan Sinielnikov, Tsai-Sheng Yang, Xiao Liang, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Ping Hao, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bozena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, Marina Nechaeva, Chia-Jui Yen, Wei-Wen Su, Yen-Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gomez-Martin, Min-Hee Ryu, Han-Sang Kim, Jee-Hyun Kim, Oleg Zarubenkov, Rashida Orlova, Elena Poddubskaya, Natalia Fadeeva, Yulia Makarova, Yee Chao, Chao-Hung Hung, Maryna Neffa, Oleksandr Vynnychenko, Adam Burgoyne, Chunyi Hao, Raphael U Mohr, Roberto Diaz-Beveridge, Jaime Feliu-Batlle, Antonio Cubillo-Gracian, Ann-Shing Lee, Bruno Daniele, Lorenzo Antonuzzo, Angelo Sangiovanni, Antonio Gasbarrini, Mario Scartozzi, Mi Sun Ahn, Sung-Yong Oh, Sergey Orlov, Hakan Harputluoglu, Berna Oksuzoglu, Chiun Hsu, Kun-Ming Rau, Oleksandr Krechkovskyi, Vladimir Yareshko, Henry Xiong, Fa-Chyi Lee, Yixing Jiang, Afshin Gabayan, Mary Crow, Christophe Van Steenkiste, Gontran Verset
|
|
| |
|
|
| |
| 11. | Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis |
| |
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1;32(8):1069-1078.doi: 10.1158/1055-9965.EPI-22-1291.
Trang VoPham # 1 2, Anne Cravero # 3, Lauren D Feld 4, Pamela Green 5, Ziding Feng 6, Kristin Berry 5, Nicole J Kim 4, Philip Vutien 4, Jason A Mendoza 7 8 9, George N Ioannou 1 4
|
|
| |
| 12. | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients |
| |
Eur J Cancer. 2023 Aug:189:112933. doi: 10.1016/j.ejca.2023.05.021. Epub 2023 Jun 1.
Mara Persano 1, Margherita Rimini 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, José Presa 10, Gianluca Masi 11, Changhoon Yoo 12, Sara Lonardi 13, Francesco Tovoli 14, Takashi Kumada 15, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Takashi Niizeki 5, Margarida Montes 10, Caterina Vivaldi 11, Caterina Soldà 13, Bernardo Stefanini 14, Atsushi Hiraoka 16, Takuya Sho 4, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 17, Giovanni Di Costanzo 18, Fabio Marra 19, Emiliano Tamburini 20, Giuseppe Cabibbo 21, Francesco Giuseppe Foschi 22, Marianna Silletta 23, Masashi Hirooka 24, Kazuya Kariyama 25, Joji Tani 26, Masanori Atsukawa 27, Koichi Takaguchi 28, Ei Itobayashi 29, Shinya Fukunishi 30, Kunihiko Tsuji 31, Toru Ishikawa 32, Kazuto Tajiri 33, Hironori Ochi 34, Satoshi Yasuda 35, Hidenori Toyoda 35, Chikara Ogawa 36, Takashi Nishimura 37, Takeshi Hatanaka 38, Satoru Kakizaki 39, Noritomo Shimada 40, Kazuhito Kawata 41, Fujimasa Tada 16, Hideko Ohama 16, Kazuhiro Nouso 25, Asahiro Morishita 26, Akemi Tsutsui 28, Takuya Nagano 28, Norio Itokawa 27, Tomomi Okubo 27, Taeang Arai 27, Michitaka Imai 32, Hisashi Kosaka 42, Atsushi Naganuma 43, Yohei Koizumi 24, Shinichiro Nakamura 3, Masaki Kaibori 42, Hiroko Iijima 37, Yoichi Hiasa 24, Claudia Campani 19, Elisabeth Amadeo 44, Federico Rossari 44, Valentina Burgio 44, Stefano Cascinu 2, Mario Scartozzi 45,&nbs |
|
| |
| 13. | Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy |
| |
Hepatol Commun. 2023 Sep 15;7(10):e0261. doi: 10.1097/HC9.0000000000000261.eCollection 2023 Oct 1.
Bernhard Scheiner 1 2 3, Katharina Lampichler 4, Katharina Pomej 1 2, Lucian Beer 4, Lorenz Balcar 1 2, Riccardo Sartoris 5, Mohamed Bouattour 6, Sabrina Sidali 6, Michael Trauner 1, Mattias Mandorfer 1, Thomas Reiberger 1, Martina Scharitzer 4, Dietmar Tamandl 4, David J Pinato 3 7, Maxime Ronot 5 8, Matthias Pinter 1 2
|
|
| |
|
|
| |
| 15. | Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study |
| |
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602.doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
Mara Persano # 1, Margherita Rimini # 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, Lorenza Rimassa 10 11, José Presa 12, Gianluca Masi 13 14, Changhoon Yoo 15, Sara Lonardi 16, Francesco Tovoli 17, Takashi Kumada 18, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Tiziana Pressiani 11, Takumi Kawaguchi 5, Margarida Montes 12, Caterina Vivaldi 13 14, Caterina Soldà 16, Fabio Piscaglia 17, Atsushi Hiraoka 19, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 20, Giovanni Di Costanzo 21, Fabio Marra 22, Mario Scartozzi 1, Emiliano Tamburini 23, Giuseppe Cabibbo 24, Francesco Giuseppe Foschi 25, Marianna Silletta 26, Masashi Hirooka 27, Kazuya Kariyama 28, Joji Tani 29, Masanori Atsukawa 30, Koichi Takaguchi 31, Ei Itobayashi 32, Shinya Fukunishi 33, Kunihiko Tsuji 34, Toru Ishikawa 35, Kazuto Tajiri 36, Hironori Ochi 37, Satoshi Yasuda 38, Hidenori Toyoda 38, Chikara Ogawa 39, Takashi Nishimura 40, Takeshi Hatanaka 41, Satoru Kakizaki 42, Noritomo Shimada 43, Kazuhito Kawata 44, Fujimasa Tada 19, Hideko Ohama
|
|
| |
| 16. | Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma in the United States: An Update |
| |
Dig Dis Sci. 2023 Oct;68(10):4050-4059. doi: 10.1007/s10620-023-08084-z.Epub 2023 Aug 16.
Yassine Kilani 1, Syeda Ashna Fatima Kamal 2, Fnu Vikash 3, Sindhu Vikash 3, Mohammad Aldiabat 4, Saqr Alsakarneh 5, Yazan Aljabiri 6, Haris Sohail 6, Vikash Kumar 7, Laith Numan 8, Kawtar Al Khalloufi 9
|
|
| |
| 17. | The Impact of a Liver Transplant Program on the Outcomes of Hepatocellular Carcinoma |
| |
Ann Surg. 2023 Aug 1;278(2):230-238. doi: 10.1097/SLA.0000000000005849.Epub 2023 Mar 30.
Yutaka Endo 1, Kazunari Sasaki 2, Zorays Moazzam 1, Selamawit Woldesenbet 1, Jason Yang 1, Henrique Araujo Lima 1, Laura Alaimo 1, Muhammad Musaab Munir 1, Chanza F Shaikh 1, Austin Schenk 1, Minoru Kitago 3, Timothy M Pawlik 1
|
|
| |
| 18. | Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients |
| |
J Cancer Res Clin Oncol. 2023 Aug;149(10):7565-7577. doi: 10.1007/s00432-023-04678-2.Epub 2023 Mar 28.
Margherita Rimini 1 2, Mara Persano 3, Toshifumi Tada 4, Goki Suda 5, Shigeo Shimose 6, Masatoshi Kudo 7, Jaekyung Cheon 8, Fabian Finkelmeier 9, Ho Yeong Lim 10, José Presa 11, Francesca Salani 12 13, Sara Lonardi 14, Fabio Piscaglia 15, Takashi Kumada 16, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Marta Schirripa 17 18, Margarida Montes 10, Caterina Vivaldi 11 12, Caterina Soldà 14, Atsushi Hiraoka 19, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Masashi Hirooka 20, Kazuya Kariyama 21, Joji Tani 22, Masanori Atsukawa 23, Koichi Takaguchi 24, Ei Itobayashi 25, Shinya Fukunishi 26, Kunihiko Tsuji 27, Toru Ishikawa 28, Kazuto Tajiri 29, Hironori Ochi 30, Satoshi Yasuda 31, Hidenori Toyoda 31, Chikara Ogawa 32, Takashi Nishimura 33, Takeshi Hatanaka 34, Satoru Kakizaki 35, Noritomo Shimada 36, Kazuhito Kawata 37, Fujimasa Tada 19, Hideko Ohama 19, Kazuhiro Nouso 21, Asahiro Morishita 22, Akemi Tsutsui 24, Takuya Nagano 24, Norio Itokawa 23, Tomomi Okubo 23, Taeang Arai 23, Michitaka Imai 28, Hisashi Kosaka 38, Atsushi Naganuma 39, Yohei Koizumi 21, Shinichiro Nakamura
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 29. | Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis |
| |
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):829-836.doi: 10.1016/S2468-1253(23)00157-7. Epub 2023 Jul 4.
Daniel Q Huang 1, Nabil Noureddin 2, Veeral Ajmera 2, Maral Amangurbanova 2, Ricki Bettencourt 2, Emily Truong 3, Tolga Gidener 4, Harris Siddiqi 2, Abdul M Majzoub 5, Tarek Nayfeh 6, Nobuharu Tamaki 7, Namiki Izumi 8, Masato Yoneda 9, Atsushi Nakajima 9, Ramazan Idilman 10, Mesut Gumussoy 10, Digdem Kuru Oz 11, Ayse Erden 11, Alina M Allen 4, Mazen Noureddin 12, Rohit Loomba 13
|
|
| |
|
|
| |
| 31. | Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC |
| |
Clin Res Hepatol Gastroenterol. 2023 Sep 2;47(8):102199. doi: 10.1016/j.clinre.2023.102199.Online ahead of print.
Sayma Chaibi 1, Edouard Larrey 1, Jean Pierre Couty 2, Philippe Sultanik 1, Claudia Campani 3, Lorraine Blaise 4, Mathilde Wagner 5, Chantal Desdouets 2, Jean Charles Nault 3, Dominique Thabut 6, Manon Allaire 7
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 35. | Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion |
| |
Eur Radiol. 2023 Jul 13. doi: 10.1007/s00330-023-09919-z. Online ahead of print.
Bachir Taouli 1, Ahmed Ba-Ssalamah 2, Julius Chapiro 3, Jagpreet Chhatwal 4, Kathryn Fowler 5, Tae Wook Kang 6, Gesine Knobloch 7, Dow-Mu Koh 8, Masatoshi Kudo 9, Jeong Min Lee 10, Takamichi Murakami 11, David J Pinato 12, Kristina I Ringe 13, Bin Song 14, Parissa Tabrizian 15, Jin Wang 16, Jeong Hee Yoon 10, Mengsu Zeng 17, Jian Zhou 18, Valérie Vilgrain 19
|
|
| |
|
|
| |
| 37. | Diagnostic approach to focal liver lesions at cross-sectional imaging: a primer for beginners |
| |
Eur Rev Med Pharmacol Sci. 2023 Aug;27(15):7201-7225.doi: 10.26355/eurrev_202308_33293.
A Borgheresi 1, A Agostini, L Pierpaoli, A Zannotti, S Capodagli-Colarizi, M Gabelloni, F De Muzio, M C Brunese, F Bruno, P Palumbo, F Grassi, R Fusco, V Granata, N Gandolfo, V Miele, A Barile, A Giovagnoni
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 42. | Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients |
| |
Cancer Immunol Immunother. 2023 Jul;72(7):1957-1969.doi: 10.1007/s00262-023-03390-x. Epub 2023 Feb 22.
Cheng-Long Han # 1, Bao-Wen Tian # 1, Lun-Jie Yan 1, Zi-Niu Ding 1, Hui Liu 1, Xin-Cheng Mao 1, Jin-Cheng Tian 1, Jun-Shuai Xue 1, Si-Yu Tan 1, Zhao-Ru Dong 1, Yu-Chuan Yan 1, Jian-Guo Hong 1, Zhi-Qiang Chen 1, Dong-Xu Wang 1, Tao Li 2
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 48. | International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance |
| |
J Hepatol. 2023 Jul;79(1):226-239.doi: 10.1016/j.jhep.2023.02.022. Epub 2023 Feb 26.
Amit G Singal 1, Marco Sanduzzi-Zamparelli 2, Pierre Nahon 3, Maxime Ronot 4, Yujin Hoshida 5, Nicole Rich 5, Maria Reig 2, Valerie Vilgrain 4, Jorge Marrero 6, Josep M Llovet 7, Neehar D Parikh 8, Augusto Villanueva 9
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 61. | Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma |
| |
Biology (Basel). 2023 Jul 11;12(7):984. doi: 10.3390/biology12070984.
Riccardo Nevola 1 2, Giovanni Tortorella 1, Valerio Rosato 2, Luca Rinaldi 1, Simona Imbriani 1, Pasquale Perillo 2, Davide Mastrocinque 2, Marco La Montagna 1, Antonio Russo 3, Giovanni Di Lorenzo 1, Maria Alfano 1, Maria Rocco 1, Carmen Ricozzi 1, Klodian Gjeloshi 1, Ferdinando Carlo Sasso 1, Raffaele Marfella 1, Aldo Marrone 1, Loreta Anesti Kondili 4, Nicolino Esposito 2, Ernesto Claar 2, Domenico Cozzolino 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 65. | Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept |
| |
Lancet Oncol. 2023 Jul;24(7):e312-e322. doi: 10.1016/S1470-2045(23)00186-9.
Alessandro Vitale 1, Giuseppe Cabibbo 2, Massimo Iavarone 3, Luca Viganò 4, David J Pinato 5, Francesca Romana Ponziani 6, Quirino Lai 7, Andrea Casadei-Gardini 8, Ciro Celsa 9, Giovanni Galati 10, Martina Gambato 11, Laura Crocetti 12, Matteo Renzulli 13, Edoardo G Giannini 14, Fabio Farinati 11, Franco Trevisani 15, Umberto Cillo 11; HCC Special Interest Group of the Italian Association for the Study of the Liver
Collaborators
- HCC Special Interest Group of the Italian Association for the Study of the Liver:
Umberto Baccarani, Giuseppina Brancaccio, Raffaele Cozzolongo, Alessandro Cucchetti, Nicoletta De Matthaeis, Stefano Di Sandro, Simone Famularo, Michele Finotti, Francesco G Foschi, Davide Ghinolfi, Marco Guarracino, Salvatore Gruttadauria, Maria Guarino, Alba Kostandini, Ilaria Lenci, Giovanni B Levi Sandri, Tommaso M Manzia, Giovanni Marasco, Mario Masarone, Chiara Mazzarelli, Fabio Melandro, Luca Miele, Filomena Morisco, Daniele Nicolini, Duilio Pagano, Filippo Pelizzaro, Giulia Pieri, Fabio Piscaglia, Maria Corina Plaz Torres, Riccardo Pravisani, Maria Rendina, Fabrizio Romano, Francesco P Russo, Rodolfo Sacco, Angelo Sangiovanni, Carlo Sposito, Raffaella Tortora, Francesco Tovoli, Mauro Viganò, Paola Violi
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 70. | LKB1 signaling and patient survival outcomes in hepatocellular carcinoma |
| |
Pharmacol Res. 2023 Jun;192:106757. doi: 10.1016/j.phrs.2023.106757.Epub 2023 Apr 5.
Khoa Nguyen 1, Katherine Hebert 2, Emily McConnell 2, Nicole Cullen 2, Thomas Cheng 2, Susanna Awoyode 2, Elizabeth Martin 2, Weina Chen 3, Tong Wu 3, Suresh K Alahari 4, Reza Izadpanah 5, Bridgette M Collins-Burow 2, Sean B Lee 3, David H Drewry 6, Matthew E Burow 7
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 81. | Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma |
| |
Sci Adv. 2023 Jun 23;9(25):eadg7038. doi: 10.1126/sciadv.adg7038. Epub 2023 Jun 21.
Solomon N Levin 1, Michael D Tomasini 1, James Knox 1, Mahsa Shirani 1, Bassem Shebl 1, David Requena 1, Jackson Clark 1, Søren Heissel 2, Hanan Alwaseem 2, Rodrigo Surjan 3, Ron Lahasky 4 5, Henrik Molina 2, Michael S Torbenson 6, Barbara Lyons 5 7, Rachael D Migler 5, Philip Coffino 1, Sanford M Simon 1 5
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 88. | Imaging of hepatocellular carcinoma recurrence after liver transplantation |
| |
Insights Imaging. 2023 May 15;14(1):84. doi: 10.1186/s13244-023-01425-6.
Giuseppe Mamone 1, Settimo Caruso 2, Mariapina Milazzo 2, Giorgia Porrello 2, Ambra Di Piazza 2, Giovanni Gentile 2, Vincenzo Carollo 2, Francesca Crinò 2, Gianluca Marrone 2, Gianvincenzo Sparacia 2, Luigi Maruzzelli 2, Roberto Miraglia 2, Salvatore Gruttadauria 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 95. | Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis |
| |
Expert Opin Drug Saf. 2023 Apr;22(4):323-329.doi: 10.1080/14740338.2023.2152793. Epub 2022 Nov 29.
Alessandro Rizzo 1, Riccardo Carloni 2, Angela Dalia Ricci 3, Antonio Cusmai 1, Mariarita Laforgia 4, Concetta Calabrò 4, Valentina Ungaro 4, Donato Oreste 5, Mario Sollitto 5, Gennaro Palmiotti 1, Giovanni Brandi 2
|
|
| |
| 96. | Liver transplantation and hepatocellular carcinoma: is TIPS deleterious? A multicentric retrospective study of the ARCHET research group with propensity score matching |
| |
Langenbecks Arch Surg. 2023 Apr 13;408(1):149. doi: 10.1007/s00423-023-02875-8.
Christophe Laurent 1, Michel Rayar 2, Charlotte Maulat 3, Fabrice Muscari 3, Arthur Marichez 4, Emilie Gregoire 5, Sophie Chopinet 5, Jean Yves Mabrut 6, Karim Boudjema 2, Mickael Lesurtel 6, Jean-Philippe Adam 4, Kayvan Mohkam 6, Laurence Chiche 4
|
|
| |
| 97. | The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 |
| |
ESMO Open. 2023 May 30;8(3):101567. doi: 10.1016/j.esmoop.2023.101567.Online ahead of print.
M Ducreux 1, G K Abou-Alfa 2, T Bekaii-Saab 3, J Berlin 4, A Cervantes 5, T de Baere 6, C Eng 4, P Galle 7, S Gill 8, T Gruenberger 9, K Haustermans 10, A Lamarca 11, P Laurent-Puig 12, J M Llovet 13, F Lordick 14, T Macarulla 15, D Mukherji 16, K Muro 17, R Obermannova 18, J-M O'Connor 19, E M O'Reilly 20, P Osterlund 21, P Philip 22, G Prager 23, E Ruiz-Garcia 24, B Sangro 25, T Seufferlein 26, J Tabernero 27, C Verslype 10, H Wasan 28, E Van Cutsem 10
|
|
| |
|
|
| |
| 99. | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
| |
Cancers (Basel). 2023 May 27;15(11):2950. doi: 10.3390/cancers15112950.
Riccardo Nevola 1 2, Augusto Delle Femine 2, Valerio Rosato 1, Loreta Anesti Kondili 3, Maria Alfano 2, Davide Mastrocinque 1, Simona Imbriani 2, Pasquale Perillo 1, Domenico Beccia 2, Angela Villani 2, Rachele Ruocco 2, Livio Criscuolo 2, Marco La Montagna 2, Antonio Russo 4, Aldo Marrone 2, Ferdinando Carlo Sasso 2, Raffaele Marfella 2, Luca Rinaldi 2, Nicolino Esposito 1, Giuseppe Barberis 5, Ernesto Claar 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 110. | Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis |
| |
Cancers (Basel). 2023 Apr 2;15(7):2122. doi: 10.3390/cancers15072122.
Victor Lopez-Lopez 1 2 3, Kohei Miura 4, Christoph Kuemmerli 5, Antonio Capel 6, Dilmurodjon Eshmuminov 7, David Ferreras 1 2, Alberto Baroja-Mazo 2, Pedro Cascales-Campos 1 2, María Isabel Jiménez-Mascuñán 1 2, José Antonio Pons 8, Maria Isabel Castellon 9, Francisco Sánchez-Bueno 1 2, Ricardo Robles-Campos 1 2, Pablo Ramírez 1 2
|
|
| |
| 111. | Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment |
| |
JGH Open. 2023 Apr 3;7(4):249-260. doi: 10.1002/jgh3.12879.eCollection 2023 Apr.
Daniel R A Cox 1 2, William Chung 3 4, Josephine Grace 3 4, Darren Wong 3 4, Numan Kutaiba 5, Dinesh Ranatunga 5, Richard Khor 6 7 8, Marcos V Perini 1 2, Michael Fink 1 2, Robert Jones 1 2 4, Mark Goodwin 5, Alex Dobrovic 1, Adam Testro 3 4, Vijayaragavan Muralidharan 1 2
|
|
| |
|
|
| |
|
|
| |
| 114. | Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference |
| |
Clin Gastroenterol Hepatol. 2023 Apr 20;S1542-3565(23)00237-9.doi: 10.1016/j.cgh.2023.03.029. Online ahead of print.
Hashem B El-Serag 1, John W Ward 2, Sumeet K Asrani 3, Amit G Singal 4, Nicole Rich 4, Aaron P Thrift 5, Salil Deshpande 6, Barbara J Turner 7, Ahmed O Kaseb 8, Ariel C Harrison 9, Brett E Fortune 10, Fasiha Kanwal 9
|
|
| |
|
|
| |
| 116. | Risk factors for HCC in contemporary cohorts of patients with cirrhosis |
| |
Hepatology. 2023 Mar 1;77(3):997-1005. doi: 10.1002/hep.32434. Epub 2023 Feb 17.
Fasiha Kanwal 1 2 3, Saira Khaderi 1, Amit G Singal 4, Jorge A Marrero 4, Nicole Loo 5, Sumeet K Asrani 6, Christopher I Amos 7, Aaron P Thrift 7, Xiangjun Gu 7, Michelle Luster 1, Abeer Al-Sarraj 1 2 3, Jing Ning 8, Hashem B El-Serag 1 2 3
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 128. | Radioembolization for Hepatocellular Carcinoma-Current Evidence and Patterns of Utilization |
| |
J Vasc Interv Radiol. 2023 Mar 29;S1051-0443(23)00254-3.doi: 10.1016/j.jvir.2023.03.020. Online ahead of print.
Hayley Briody 1, David Duong 2, Sern Wei Yeoh 3, Russell Hodgson 4, Tuck Leong Yong 4, Anthony Hannah 5, Michael J Lee 6, Sum Leong 7, Julian Maingard 8, Hamed Asadi 9, Hong Kuan Kok 10
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 134. | Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score |
| |
PLoS One. 2023 Feb 28;18(2):e0282309. doi: 10.1371/journal.pone.0282309. eCollection 2023.
Aaron P Thrift 1 2, Fasiha Kanwal 3 4, Yanhong Liu 1 2, Saira Khaderi 3, Amit G Singal 5, Jorge A Marrero 5, Nicole Loo 6, Sumeet K Asrani 7, Michelle Luster 3, Abeer Al-Sarraj 3 4, Jing Ning 8, Spiridon Tsavachidis 1, Xiangjun Gu 1, Christopher I Amos 1 2, Hashem B El-Serag 3 4
|
|
| |
|
|
| |
| 136. | Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification |
| |
Ann Surg Oncol. 2023 Feb;30(2):750-759. doi: 10.1245/s10434-022-12832-2.Epub 2022 Nov 20.
Zorays Moazzam 1, Laura Alaimo 1 2, Yutaka Endo 1, Henrique A Lima 1, Chanza F Shaikh 1, Francesca Ratti 3, Hugo P Marques 4, François Cauchy 5, Vincent Lam 6, George A Poultsides 7, Irinel Popescu 8, Sorin Alexandrescu 8, Guillaume Martel 9, Alfredo Guglielmi 2, Tom Hugh 10, Luca Aldrighetti 3, Itaru Endo 11, Timothy M Pawlik 12
|
|
| |
|
|
| |
|
|
| |
| 139. | Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study |
| |
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):921-928.doi: 10.1007/s00259-022-06002-5. Epub 2022 Oct 25.
Jules Gregory 1 2 3 4, Lambros Tselikas 5, Caroline Allimant 6, Thierry de Baere 5, Irene Bargellini 7, Jon Bell 8, José Ignacio Bilbao 9, Antoine Bouvier 10, Julius Chapiro 11, Carlo Chiesa 12, Thomas Decaens 13, Alban Denys 14, Rafael Duran 14, Julien Edeline 15, Etienne Garin 16, Julien Ghelfi 13, Thomas Helmberger 17, Farah Irani 18, Marnix Lam 19, Robert Lewandowski 20, David Liu 21, Romaric Loffroy 22, David C Madoff 11, Charles Mastier 23, Riad Salem 20, Bruno Sangro 24, Daniel Sze 25, Valérie Vilgrain 26 27, Michael Vouche 28, Boris Guiu 6, Maxime Ronot 26 27
|
|
| |
|
|
| |
| 141. | LI-RADS: Looking Back, Looking Forward |
| |
Radiology. 2023 Apr;307(1):e222801. doi: 10.1148/radiol.222801. Epub 2023 Feb 28.
Victoria Chernyak 1, Kathryn J Fowler 1, Richard K G Do 1, Aya Kamaya 1, Yuko Kono 1, An Tang 1, Donald G Mitchell 1, Jeffrey Weinreb 1, Cynthia S Santillan 1, Claude B Sirlin 1
|
|
| |
| 142. | Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial |
| |
Clin Oncol. 2023 Mar 20;41(9):1747-1757.doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13.
Thomas Yau 1, Vittorina Zagonel 2, Armando Santoro 3 4, Mirelis Acosta-Rivera 5, Su Pin Choo 6, Ana Matilla 7 8, Aiwu Ruth He 9, Antonio Cubillo Gracian 10 11, Anthony B El-Khoueiry 12, Bruno Sangro 13, Tarek E Eldawy 14, Jordi Bruix 15, Giovanni Luca Frassineti 16, Gina M Vaccaro 17, Marina Tschaika 18, Christian Scheffold 19, Petra Koopmans 18, Jaclyn Neely 18, Fabio Piscaglia 20
|
|
| |
| 143. | Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI |
| |
J Magn Reson Imaging. 2023 Mar 5. doi: 10.1002/jmri.28659. Online ahead of print.
Richa Patel 1, Anum Aslam 2, Neehar D Parikh 3, Benjamin Mervak 2, Eman Mubarak 2, Lily Higgins 2, Kayli Lala 2, Jack F Conner 4, Valerie Khaykin 5, Mustafa Bashir 6, Richard Kinh Gian Do 7, Lauren M B Burke 8, Elainea N Smith 9, Charles Y Kim 6, Kimberly L Shampain 2, Dawn Owen 10, Mishal Mendiratta-Lala 2
|
|
| |
|
|
| |
| 145. | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin |
| |
Aliment Pharmacol Ther. 2023 Mar;57(6):600-609. doi: 10.1111/apt.17371.Epub 2023 Jan 10.
Rebecca W Zeng 1, Jie Ning Yong 1, Darren J H Tan 1, Clarissa E Fu 1, Wen Hui Lim 1, Jieling Xiao 1, Kai En Chan 1, Caitlyn Tan 1, Xin Lei Goh 1, Douglas Chee 2, Nicholas Syn 1, Eunice X Tan 1 2 3, Mark D Muthiah 1 2 3, Cheng Han Ng 1, Nobuharu Tamaki 4, Sung Won Lee 5 6, Beom Kyung Kim 7 8, Mindie H Nguyen 9, Rohit Loomba 10, Daniel Q Huang 1 2 3 10
|
|
| |
| 146. | Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada |
| |
Cancer Treat Rev. 2023 Apr;115:102526. doi: 10.1016/j.ctrv.2023.102526.Epub 2023 Mar 2.
Jason K Wong 1, Howard J Lim 2, Vincent C Tam 3, Kelly W Burak 4, Laura A Dawson 5, Prosanto Chaudhury 6, Robert J Abraham 7, Brandon M Meyers 8, Gonzalo Sapisochin 9, David Valenti 10, Setareh Samimi 11, Ravi Ramjeesingh 12, Amol Mujoomdar 13, Ilidio Martins 14, Elijah Dixon 15, Maja Segedi 16, David M Liu 17
|
|
| |
|
|
| |
|
|
| |
| 149. | Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma |
| |
Clin Cancer Res. 2023 Feb 16;29(4):754-763.doi: 10.1158/1078-0432.CCR-22-1983.
Xuyang Song 1, Robin Kate Kelley 2, Anis A Khan 1, Nathan Standifer 3, Diansong Zhou 4, KyoungSoo Lim 1, Rajesh Krishna 5, Lu Liu 6, Kun Wang 6, Patricia McCoon 7, Alejandra Negro 8, Philip He 9, Megan Gibbs 1, John F Kurland 10, Ghassan K Abou-Alfa 11 12
|
|
| |
| 150. | Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial |
| |
Dig Liver Dis. 2023 Apr;55(4):464-470.doi: 10.1016/j.dld.2023.01.161. Epub 2023 Feb 16.
Philippe Merle 1, Jean-Frédéric Blanc 2, Julien Edeline 3, Karine Le Malicot 4, Manon Allaire 5, Eric Assenat 6, Meriem Guarssifi 4, Mohamed Bouattour 7, Jean-Marie Péron 8, Pierre Laurent-Puig 9, Massimo Levrero 10, Charlotte Costentin 11, Boris Guiu 12, Harry Sokol 13, David Tougeron 14, Thomas Aparicio 15, Jean-Charles Nault 16, Jean-Marc Phelip 17
|
|
| |
|
|
| |
| 152. | Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population |
| |
Eur J Cancer. 2023 Feb;180:9-20.doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Andrea Casadei-Gardini 1, Margherita Rimini 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, Lorenza Rimassa 10, José Presa 11, Gianluca Masi 12, Changhoon Yoo 13, Sara Lonardi 14, Francesco Tovoli 15, Takashi Kumada 16, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Tiziana Pressiani 17, Margarida Montes 11, Caterina Vivaldi 12, Caterina Soldà 14, Fabio Piscaglia 15, Atsushi Hiraoka 18, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 19, Giovanni Di Costanzo 20, Fabio Marra 21, Mario Scartozzi 22, Emiliano Tamburini 23, Giuseppe Cabibbo 24, Francesco Giuseppe Foschi 25, Marianna Silletta 26, Masashi Hirooka 27, Kazuya Kariyama 28, Joji Tani 29, Masanori Atsukawa 30, Koichi Takaguchi 31, Ei Itobayashi 32, Shinya Fukunishi 33, Kunihiko Tsuji 34, Toru Ishikawa 35, Kazuto Tajiri 36, Hironori Ochi 37, Satoshi Yasuda 38, Hidenori Toyoda 38, Chikara Ogawa 39, Takashi Nishimura 40, Takeshi Hatanaka 41, Satoru Kakizaki 42, Noritomo Shimada 43, Kazuhito Kawata 44, Fujimasa Tada 18, Hideko Ohama 18, Kazuhiro Nouso 28, Asahiro Morishita 29, Akemi Tsutsui 31, Takuya Nagano 31, Norio Itokawa 30, Tomomi Okubo 30, Taeang Arai 30, Michitaka Imai 35, Hisashi Kosaka 45, Atsushi Naganuma 46, Yohei Koizumi 28, Shinichiro Nakamura 3, Masaki Kaibori 45, Hiroko Iijima 40, Yoichi Hiasa 27, Valentina Burgio 2, Mara Persano 22, Angelo Della Corte 47, Francesca Ratti 48, Francesco De Cobelli 47< |
|
| |
|
|
| |
| 154. | Predictors of early and late hepatocellular carcinoma recurrence |
| |
World J Gastroenterol. 2023 Feb 28;29(8):1243-1260. doi: 10.3748/wjg.v29.i8.1243.
Riccardo Nevola 1 2, Rachele Ruocco 1, Livio Criscuolo 1, Angela Villani 1, Maria Alfano 1, Domenico Beccia 1, Simona Imbriani 1, Ernesto Claar 3, Domenico Cozzolino 1, Ferdinando Carlo Sasso 1, Aldo Marrone 1, Luigi Elio Adinolfi 1, Luca Rinaldi 1
|
|
| |
|
|
| |
| 156. | Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery |
| |
AMA Surg. 2023 Feb 1;158(2):192-202. doi: 10.1001/jamasurg.2022.6697.
Simone Famularo 1 2, Matteo Donadon 1 2, Federica Cipriani 3, Federico Fazio 4, Francesco Ardito 5, Maurizio Iaria 6, Pasquale Perri 7, Simone Conci 8, Tommaso Dominioni 9, Quirino Lai 10, Giuliano La Barba 11, Stefan Patauner 12, Sarah Molfino 13, Paola Germani 14, Giuseppe Zimmitti 15, Enrico Pinotti 16, Matteo Zanello 17, Luca Fumagalli 18, Cecilia Ferrari 19, Maurizio Romano 20 21, Antonella Delvecchio 22, Maria Grazia Valsecchi 23, Adelmo Antonucci 24, Fabio Piscaglia 25, Fabio Farinati 26, Yoshikuni Kawaguchi 27, Kiyoshi Hasegawa 27, Riccardo Memeo 22, Giacomo Zanus 20 21, Guido Griseri 19, Marco Chiarelli 18, Elio Jovine 17, Mauro Zago 16 18, Moh'd Abu Hilal 15, Paola Tarchi 14, Gian Luca Baiocchi 13, Antonio Frena 12, Giorgio Ercolani 11, Massimo Rossi 10, Marcello Maestri 9, Andrea Ruzzenente 8, Gian Luca Grazi 7, Raffaele Dalla Valle 6, Fabrizio Romano 28, Felice Giuliante 5, Alessandro Ferrero 4, Luca Aldrighetti 3, Davide P Bernasconi 23, Guido Torzilli 1 2; HE.RC.O.LE.S. Group
|
|
| |
|
|
| |
|
|
| |
| 159. | Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies |
| |
Biomedicines. 2023 Feb 6;11(2):468. doi: 10.3390/biomedicines11020468.
Erica Vetrano 1, Luca Rinaldi 1, Andrea Mormone 1, Chiara Giorgione 1, Raffaele Galiero 1, Alfredo Caturano 1, Riccardo Nevola 1, Raffaele Marfella 1, Ferdinando Carlo Sasso 1
|
|
| |
|
|
| |
|
|
| |
|
|
| |
| 163. | HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma |
| |
Hepatology. 2023 Mar 1;77(3):774-788. doi: 10.1002/hep.32692. Epub 2023 Feb 17.
Na Sun 1 2, Ceng Zhang 1 3, Yi-Te Lee 1, Benjamin V Tran 4, Jing Wang 1, Hyoyong Kim 1, Junseok Lee 1, Ryan Y Zhang 1, Jasmine J Wang 1 5, Junhui Hu 6, Zhicheng Zhang 6, Manaf S Alsudaney 7, Kuan-Chu Hou 1, Hubert Tang 1, Tiffany X Zhang 1, Icy Y Liang 1, Ziang Zhou 1, Mengxiang Chen 1, Angela Hsiao-Jiun Yeh 8, Wenyuan Li 9, Xianghong Jasmine Zhou 9, Helena R Chang 4, Steven-Huy B Han 8, Saeed Sadeghi 8, Richard S Finn 8, Sammy Saab 8, Ronald W Busuttil 4, Mazen Noureddin 7 10, Walid S Ayoub 7 10, Alexander Kuo 7 10, Vinay Sundaram 7 10, Buraq Al-Ghaieb 7 10, Juvelyn Palomique 7, Kambiz Kosari 7, Irene K Kim 7, Tsuyoshi Todo 7, Nicholas N Nissen 7, Maria Lauda Tomasi 10, Sungyong You 11, Edwin M Posadas 5, James X Wu 4, Madhuri Wadehra 9, Myung-Shin Sim 12, Yunfeng Li 9, Hanlin L Wang 9, Samuel W French 9, Shelly C Lu 10 13, Lily Wu 6, Renjun Pei 2, Li Liang 14 15, Ju Dong Yang 7 10 13, Vatche G Agopian 4 16, Hsian-Rong Tseng 1 16, Yazhen Zhu 1 9 16
|
|
| |
|
|
| |
|
| | | | | |
